98%
921
2 minutes
20
A review of decompression sickness (DCS) cases associated with the NASA altitude physiological training (APT) program at the Johnson Space Center (JSC) motivated us to place our findings into the larger context of DCS prevalence from other APT centers. We reviewed JSC records from 1999 to 2016 and 14 publications from 1968 to 2004 about DCS prevalence in other APT programs. We performed a meta-analysis of 15 APT profiles (488 cases / 385,116 exposures). We used meta-regression to evaluate the relation between estimated exposures and probability of DCS in a test group, accounting for the heterogeneity between studies. Our in-house review identified 6 Type I DCS (1 from an inside observer) and 1 Type II DCS. There were 6 cases in 9560 student hypobaric exposures from 3 NASA training flights; a student pooled prevalence rate of 0.44 cases / 1000 exposures compared to 1.44 cases / 1000 from 12 published APT profiles. The overall pooled DCS prevalence rate was 1.16 cases / 1000 exposures. There was substantial heterogeneity in DCS prevalence across studies. Denitrogenation time, exposure pressure, and exposure time were associated with probability of DCS in the meta-regression model. While the overall DCS prevalence rate is relatively low, there is marked heterogeneity among profiles. The pooled DCS prevalence rate estimate for the NASA profiles was lower than the overall rate. Variability in APT profile DCS prevalence could be further explained given student level and additional test-level covariates.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3357/AMHP.5135.2018 | DOI Listing |
Front Immunol
September 2025
Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Background: Tertiary lymphoid structures (TLSs) are linked to prognosis in esophageal squamous cell carcinoma (ESCC), but whether the distribution, abundance, and maturity of TLSs affect therapeutic efficacy and prognosis in ESCC treated with neoadjuvant chemoradiotherapy plus immunotherapy (NRCI) remains unclear. We explored TLS characteristics and correlated them with patient survival.
Methods: A total of 157 resectable ESCC patients treated with neoadjuvant therapy between September 2020 and May 2023 were divided into NRCI (n=49) and neoadjuvant chemoimmunotherapy (NCI, n=108) groups.
Sci Adv
August 2025
Department of Molecular Pathology and Biology, Military Faculty of Medicine, University of Defence, 500 01 Hradec Kralove, Czechia.
Dendritic cells (DCs) hijacked by intracellular bacteria contribute to pathogen dissemination and immunopathology. How bacteria achieve DC subversion remains largely unknown. Here, we describe the mechanism used by tularemia agent exploiting host mitochondrial anaplerosis.
View Article and Find Full Text PDFSci Rep
August 2025
The Third School of Clinical Medicine, School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor. Current therapies (temozolomide/radiotherapy) often encounter resistance, necessitating novel molecular targets. Bioinformatics analysis was performed for the data obtained from TCGA, COSMIC, cbioPortal, and MethSurv databases.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Gastroenterology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
The interplay between the gut microbiota, bile acid (BA) metabolism, and the tumor immune microenvironment (TIME) is a critical and rapidly advancing field in cancer immunology. Microbiota-transformed bile acids act as pivotal signaling molecules. This review systematically dissects how these BAs engage host receptors (e.
View Article and Find Full Text PDFInt J Clin Exp Pathol
July 2025
Laboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University Rome 00161, Italy.
Immune checkpoint inhibitors are increasingly used in neoadjuvant non-small cell lung carcinoma (NSCLC). Data regarding histologic features of the tumor microenvironment in this group of patients are limited. This study aimed to analyze the histologic features and the immune cell infiltrates within the tumor microenvironment of NSCLC after neoadjuvant immunotherapy.
View Article and Find Full Text PDF